The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
Open accessAbstract
The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) are still to be investigated. Here, we studied the functional significance and the druggability of the oncogenic lncRNA MALAT1 in MM. Targeting MALAT1 by novel LNA-gapmeR antisense oligonucleotide antagonized MM cell proliferation and triggered apoptosis both in vitro and in vivo in a murine xenograft model of human MM. Of note, antagonism of MALAT1 downmodulated the two major transcriptional activators of proteasome subunit genes, namely NRF1 and NRF2, and resulted in reduced trypsin, chymotrypsin and caspase-like proteasome activities and in accumulation of polyubiquitinated proteins. NRF1 and NRF2 decrease upon MALAT1 targeting was due to transcriptional activation of their negative regulator KEAP1, and resulted in reduced expression of anti-oxidant genes and increased ROS levels. In turn, NRF1 promoted MALAT1 expression thus establishing a positive feedback loop. Our findings demonstrate a crucial role of MALAT1 in the regulation of the proteasome machinery, and provide proof-of-concept that its targeting is a novel powerful option for the treatment of MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Long Noncoding RNAs
Wang, K. C., & Chang, H. Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.018 · Cited by 4,396
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
The ubiquitin-proteasome proteolytic pathway
Ciechanover, A. (1994) · Cell · doi:10.1016/0092-8674(94)90396-4 · Cited by 1,791
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Venugopal, R., & Jaiswal, A. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14960 · Cited by 1,040
Molecular basis of the Keap1–Nrf2 system
Suzuki, T., & Yamamoto, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.006 · Cited by 995
MALAT1 — a paradigm for long noncoding RNA function in cancer
Gutschner, T., Hämmerle, M., & Diederichs, S. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1028-y · Cited by 719
Evolutionary conservation of long non-coding RNAs; sequence, structure, function
Johnsson, P., Lipovich, L., Grandér, D., & Morris, K. V. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.035 · Cited by 705
Targeting noncoding RNAs in disease
Adams, B. D., Parsons, C., Walker, L., Zhang, W. C., & Slack, F. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci84424 · Cited by 673
Melanoma addiction to the long non-coding RNA SAMMSON
Leucci, E., Vendramin, R., Spinazzi, M., Laurette, P., Fiers, M., Wouters, J., Radaelli, E., Eyckerman, S., Leonelli, C., Vanderheyden, K., et al. (2016) · Nature · doi:10.1038/nature17161 · Cited by 582
Hirata, H., Hinoda, Y., Shahryari, V., Deng, G., Nakajima, K., Tabatabai, Z. L., Ishii, N., & Dahiya, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2931 · Cited by 551
Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets
Chandra Gupta, S., & Nandan Tripathi, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.30546 · Cited by 527
Lennox, K. A., & Behlke, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1206 · Cited by 453
Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp841 · Cited by 360
Coordinated regulation of protein synthesis and degradation by mTORC1
Zhang, Y., Nicholatos, J., Dreier, J. R., Ricoult, S. J. H., Widenmaier, S. B., Hotamisligil, G. S., Kwiatkowski, D. J., & Manning, B. D. (2014) · Nature · doi:10.1038/nature13492 · Cited by 350
Junk DNA and the long non-coding RNA twist in cancer genetics
Ling, H., Vincent, K., Pichler, M., Fodde, R., Berindan-Neagoe, I., Slack, F. J., & Calin, G. A. (2015) · Oncogene · doi:10.1038/onc.2014.456 · Cited by 328
From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis
Dhamija, S., & Diederichs, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30039 · Cited by 272
Arlt, A., Bauer, I., Schafmayer, C., Tepel, J., Müerköster, S. S., Brosch, M., Röder, C., Kalthoff, H., Hampe, J., Moyer, M. P., et al. (2009) · Oncogene · doi:10.1038/onc.2009.264 · Cited by 244
Current treatment landscape for relapsed and/or refractory multiple myeloma
Dimopoulos, M. A., Richardson, P. G., Moreau, P., & Anderson, K. C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.200 · Cited by 195
Chauhan, D., Singh, A., Brahmandam, M., Podar, K., Hideshima, T., Richardson, P., Munshi, N., Palladino, M. A., & Anderson, K. C. (2008) · Blood · doi:10.1182/blood-2007-08-105601 · Cited by 190
Self-citationMolecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
Progress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 169
Ma, X., Wang, J., Wang, J., Charles, X., Wang, X., & Liu, F. (2015) · BMC Genomics · doi:10.1186/s12864-015-1881-x · Cited by 149
Gullà, A., Martino, M. T. D., Cantafio, M. E. G., Morelli, E., Amodio, N., Botta, C., Pitari, M. R., Lio, S. G., Britti, D., Stamato, M. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0489 · Cited by 127
Self-citationTherapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Amodio, N., Stamato, M. A., Gullà, A., Morelli, E., Romeo, E., Raimondi, L., Pitari, M. R., Ferrandino, I., Misso, G., Caraglia, M., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0985 · Cited by 125
Self-citationSynthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
Cottini, F., Hideshima, T., Suzuki, R., Tai, Y., Bianchini, G., Richardson, P. G. G., Anderson, K. C., & Tonon, G. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0943 · Cited by 118
Pitari, M. R., Rossi, M., Amodio, N., Botta, C., Morelli, E., Federico, C., Gullà, A., Caracciolo, D., Martino, M. T. D., Arbitrio, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4398 · Cited by 104
Self-citationDistinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma
Ronchetti, D., Agnelli, L., Taìana, E., Galletti, S., Manzoni, M., Todoerti, K., Musto, P., Strozzi, F., & Neri, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7442 · Cited by 104
Self-citationLee, C. S., Ho, D. V., & Chan, J. Y. (2013) · FEBS Journal · doi:10.1111/febs.12350 · Cited by 99
Li, B.-Z., Fu, J., Chen, P., Ge, X., Li, Y., Kuiatse, I., Wang, H., Wang, H., Zhang, X., & Orlowski, R. Z. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664953 · Cited by 82
Biswas, M., Phan, D., Watanabe, M., & Chan, J. Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.253807 · Cited by 75
Kato, L. M., Begum, N. A., Burroughs, A. M., Doi, T., Kawai, J., Daub, C. O., Kawaguchi, T., Matsuda, F., Hayashizaki, Y., & Honjo, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120791109 · Cited by 72
Zhang, Y., Qu, Z., Kim, S., Shi, V., Liao, B., Kraft, P., Bandaru, R., Wu, Y. S., Greenberger, L. M., & Horak, I. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.133 · Cited by 71
MicroRNA theragnostics for the clinical management of multiple myeloma
Ahmad, N., Haider, S. A., Jagannathan, S., Anaissie, E. J., & Driscoll, J. J. (2013) · Leukemia · doi:10.1038/leu.2013.262 · Cited by 70
Amodio, N., D’Aquila, P., Passarino, G., Tassone, P., & Bellizzi, D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1266339 · Cited by 69
Self-citationLong non-coding RNAs in normal and malignant hematopoiesis
Nobili, L., Lionetti, M., & Neri, A. (2016) · Oncotarget · doi:10.18632/oncotarget.9308 · Cited by 65
Self-citationKnockdown of Nuclear-Located Enhancer RNAs and Long ncRNAs Using Locked Nucleic Acid GapmeRs
Roux, B. T., Lindsay, M. A., & Heward, J. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-4035-6_2 · Cited by 25
Cited by
Yan, H., & Bu, P. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200032 · Cited by 667
Long non-coding RNAs: From disease code to drug role
Chen, Y., Li, Z., Chen, X., & Zhang, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.001 · Cited by 503
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer
Goyal, B., Yadav, S. R. M., Awasthee, N., Gupta, S., Kunnumakkara, A. B., & Gupta, S. C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188502 · Cited by 358
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
Amodio, N., Raimondi, L., Juli, G., Stamato, M. A., Caracciolo, D., Tagliaferri, P., & Tassone, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0606-4 · Cited by 348
Self-citationMALAT1 Long Non-Coding RNA: Functional Implications
Arun, G., Aggarwal, D., & Spector, D. L. (2020) · Non-Coding RNA · doi:10.3390/ncrna6020022 · Cited by 276
Metadata
- Authors
- Amodio, N., Stamato, M. A., Juli, G., Morelli, E., Fulciniti, M., Manzoni, M., Taiana, E., Agnelli, L., Cantafio, M. E. G., Romeo, E., Raimondi, L., Caracciolo, D., Zuccalà, V., Rossi, M., Neri, A., Munshi, N. C., Tagliaferri, P., & Tassone, P.
- Venue
- Leukemia
- Published
- 2018-02-22
- Volume
- 32
- Issue
- 9
- Pages
- 1948-1957
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2794096909
- Cited by
- 260
- References
- 39
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.